Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (5)

NSP3 (1)

ComplexRdRp (1)

ORF7a (1)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 61 - 65 records in total 65
    records per page




    Natural Product Compounds in Alpinia officinarum and Ginger are Potent SARS-CoV-2 Papain-like Protease PROTEIN Inhibitors

    Authors: Dibakar Goswami; Mukesh Kumar; Sunil K. Ghosh; Amit Das

    doi:10.26434/chemrxiv.12071997.v1 Date: 2020-04-06 Source: ChemRxiv

    SARS-CoV-2 or COVID-19 MESHD has caused more than 10,00,000 infections and ~55,000 deaths worldwide spanning over 203 countries, and the numbers are exponentially increasing. Due to urgent need of treating the SARS infection MESHD, many approved, pre-clinical, anti-viral, anti- malarial MESHD and anti-SARS drugs are being administered to patients. SARS-CoV-2 papain-like protease PROTEIN ( PLpro PROTEIN) has a protease domain which cleaves the viral polyproteins a/b, necessary for its survival and replication, and is one of the drug target against SARS-CoV-2. 3D structures of SARS-CoV-2 PLpro PROTEIN were built by homology modelling. Two models having partially open and closed conformations were used in our study. Virtual screening of natural product compounds was performed. We prepared an in house library of compounds found in rhizomes, Alpinia officinarum, ginger and curcuma, and docked them into the solvent accessible S3-S4 pocket of PLpro PROTEIN. Eight compounds from Alpinia officinarum and ginger bind with high in silico affinity to closed PLpro PROTEIN conformer, and hence are potential SARS-CoV-2 PLpro PROTEIN inhibitors. Our study reveal new lead compounds targeting SARS-CoV-2. Further structure based modifications or extract formulations of these compounds can lead to highly potent inhibitors to treat SARS-CoV-2 infections MESHD.

    Information Mining for COVID-19 MESHD Research From a Large Volume of Scientific Literature

    Authors: Sabber Ahamed; Manar Samad

    id:2004.02085v1 Date: 2020-04-05 Source: arXiv

    The year 2020 has seen an unprecedented COVID-19 MESHD COVID-19 MESHD pandemic due to the outbreak of a novel strain of coronavirus in 180 countries. In a desperate effort to discover new drugs and vaccines for COVID-19 MESHD, many scientists are working around the clock. Their valuable time and effort may benefit from computer-based mining of a large volume of health science literature that is a treasure trove of information. In this paper, we have developed a graph-based model using abstracts of 10,683 scientific articles to find key information on three topics: transmission, drug types, and genome research related to coronavirus. A subgraph is built for each of the three topics to extract more topic-focused information. Within each subgraph, we use a betweenness centrality measurement to rank order the importance of keywords related to drugs, diseases, pathogens, hosts of pathogens, and biomolecules. The results reveal intriguing information about antiviral drugs (Chloroquine, Amantadine, Dexamethasone), pathogen-hosts (pigs, bats, macaque, cynomolgus), viral pathogens (zika, dengue, malaria MESHD, and several viruses in the coronaviridae virus family), and proteins and therapeutic mechanisms (oligonucleotide, interferon, glycoprotein) in connection with the core topic of coronavirus. The categorical summary of these keywords and topics may be a useful reference to expedite and recommend new and alternative directions for COVID-19 MESHD research.

    Bioinformatics approaches to understand the interactions between the SARS corona Virus (SARS-CoV19) with stranded drugs of anti-retro viral treatment, Influenza and Malaria.

    Authors: Santhoshi Rani Nanchari; Shyam perugu

    doi:10.21203/rs.3.rs-20010/v1 Date: 2020-03-28 Source: ResearchSquare

    Background: Severe acute respiratory syndrome MESHD (SARS) is highly contagious disease caused by virus COVID19 MESHD. The first case is reported in Wuhan, China, with rapid spreading all over the world and the rate of mortality is also high. SARS-CoV MESHD and another human coronavirus, HCoV-NL63 has large spike protein (S PROTEIN) on the virion surface mediates both cell attachment and membrane fusion with receptor sites present on host cell-surface zinc peptidase, angiotensin-converting enzyme 2 (ACE2). Methodology: In the present study, molecular docking studies have been carried out to assess the interaction between the novel corona virus protein COVID19 MESHD with stranded drugs used for influenza, anti-retro viral therapy and malaria MESHD drugs by using Accelerys discovery studio 2.5, followed by analysis of data. The present study will help to design the drugs against the corona virus and understand the mode of treatment for SARS. Results: All the four-protein receptor of COVID 19 proteins at particular amino acid position binds to the NH and H atom of anti-retro viral therapy drugs (Atazanavir, Doravirine, Emitricitabine, Entravirine, Raltegravir, Tenofavir Disproxil, and Zidovudin) and anti- malaria MESHD drug (Hydroxy chloroquine) with less hydrogen bond distance with maximum docking scores which indicates that these compounds can acts against the COVID19 MESHD virus. Gene mania MESHD network help to design the novel drugs and diagnosis. Conclusions: This is first report to show the molecular docking interaction between the COVID19 MESHD protein with stranded drugs of anti -viral treatment. anti-viral drugs Atazanavir, Doravirine, Emitricitabine, Entravirine, Raltegravir, Tenofavir Disproxil, and Zidovudin and malaria drug Hydroxy MESHD chloroquine has more strong binding with COVID19 MESHD protein receptors.

    Repositioning Chloroquine as Ideal Antiviral Prophylactic against COVID-19 MESHD - Time is Now

    Authors: Raymond Chang; Wei-Zen Sun

    id:10.20944/preprints202003.0279.v1 Date: 2020-03-17 Source: Preprints.org

    The novel coronavirus 2019 ( COVID-19 MESHD) pandemic is rapidly advancing despite public health measures. Pharmaceutical prophylaxis is an established approach to potentially control infectious diseases MESHD and is one solution to the urgent public health challenge posed by COVID-19 MESHD. Screening and development of new vaccines and antivirals is expensive and time consuming while the repositioning of available drugs should receive priority attention as well as international government and agency support. Here we propose an old drug chloroquine (CQ) to be urgently repositioned as an ideal antiviral prophylactic against COVID-19 MESHD. CQ has ability to block viral attachment and entry to host cells. Its proven clinical efficacy against a variety of viruses including COVID-19 MESHD and its current deployment in COVID-19 MESHD therapeutic trials strengthens its potential candidacy as a prophylactic. Furthermore, CQ has a long safety record, is inexpensive and widely available. Here we reviewed CQ's antiviral mechanisms, its laboratory efficacy activity against COVID-19 MESHD, as well as CQ's pharmacokinetics in its established use against malaria MESHD and autoimmune diseases MESHD to recommend safe and potentially efficacious dose regimens for protection against COVID-19 MESHD: a pre-exposure prophylaxis of 250-500mg daily and post-exposure prophylaxis at 8mg/kg/day for 3 days. We recommend further urgent research on CQ for COVID-19 MESHD prevention and urge that the above regimens be investigated in parallel with mass deployment by relevant agencies in attempts to contain the pandemic without unnecessary regulatory delays as benefits far outweigh risks or costs.

    Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19 MESHD

    Authors: Meehyun Ko; So Young Chang; Soo Young Byun; Inhee Choi; David Shum; Ji-Young Min; Marc P. Windisch

    doi:10.1101/2020.02.25.965582 Date: 2020-03-02 Source: bioRxiv

    In 2015, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV MESHD) reached the Republic of Korea through nosocomial transmission and was the largest epidemic outside of the Arabian Peninsula. To date, despite various strategies to identify CoV interventions, only limited therapeutic options are available. To address these unmet medical needs, we used a South Korean MERS-CoV clinical isolate and screened 5,406 compounds, including United States Food and Drug Administration (FDA)-approved drugs and bioactive molecules, for their activity against the isolate. The primary assay confirmed 221 hits by dose-response curve analysis and identified 54 hits with a therapeutic index (TI) greater than 6. Time-of-addition studies with 12 FDA-approved drugs demonstrated that 8 and 4 therapeutics act on the early and late stages of the viral life cycle, respectively. Among the drugs were e.g., three cardiotonic agents (ouabain, digitoxin, digoxin) with a TI greater than 100, an anti- malaria MESHD drug (atovaquone; TI >34), an inhalable corticosteroid (ciclesonide; TI >6), etc. Together, our results identify potential therapeutic options for treating MERS-CoV infections MESHD and could provide a basis for agents against a wider range of coronavirus-related illnesses, including the currently emerging Coronavirus Disease MESHD Coronavirus Disease 2019 MESHD ( COVID-19 MESHD) outbreak.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.